Please login to the form below

brentuximab vedotin

This page shows the latest brentuximab vedotin news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics claims key US approval for Adcetris

Adcetris (brentuximab vedotin), an antibody-drug conjugate, is the first new treatment for this type of lymphoma in more than 40 years, with the US regulator approving it for use alongside ... Seattle has since turned its attention to its own TNBC

Latest news

Takeda bags EU approval for Adcetris in lymphoma

CTCL). Adcetris (brentuximab vedotin) - a CD30-targeting antibody drug conjugate (ADC) - already has conditional approval in the EU for certain adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma, but
Seattle Genetics' Adcetris earns FDA priority review status

Adcetris (brentuximab vedotin), an antibody-drug conjugate, was awarded the status based on the results of the phase III ECHELON-1 trial, which had a primary endpoint of an improved PFS
NICE reverses stance on Takeda’s Adcetris

Takeda has claimed a partial win for its non-Hodgkin’s lymphoma drug Adcetris (brentuximab vedotin) after persuading NICE to change its mind and issue new draft guidance. ... I am delighted that patients can maintain long term access to Brentuximab
Keytruda and Opdivo backed for new uses in Europe

Keytruda is cleared for use in adults who have failed a stem cell transplant and have already tried or are ineligible for Takeda's Adcetris (brentuximab vedotin).
Keytruda claims first blood cancer OK from FDA

brentuximab vedotin), so Merck is playing catch-up in this indication. ... prior stem cell transplantation or use of brentuximab vedotin.".

More from news
Approximately 3 fully matching, plus 25 partially matching documents found.

Latest Intelligence

Interview: Trevor Smith, Takeda

Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July and which Takeda expects to launch

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Account Manager – Med Comms – London: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Account Manager or AD - Medical Communications: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Scientific Director: Great salary and bebefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Medical Writer: Great salary and benefits

Senior Programme Executive: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Manager / Account Director: Great salary and bebefits

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and bebefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Subscribe to our email news alerts

PMHub

Add my company

Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...